UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 5.595

Sortiert nach

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2183-2189

2012

Link zum Volltext

Verfügbarkeit prüfen

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Blood, 2015-02, Vol.125 (8), p.1236-1243

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Blood, 2012-07, Vol.120 (3), p.560-568

2012

Link zum Volltext

Verfügbarkeit prüfen

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era

Journal of clinical oncology, 2010-02, Vol.28 (6), p.1038-1046

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Blood, 2016-11, Vol.128 (21), p.2510-2516

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

The Lancet. Haematology, 2017-04, Vol.4 (4), p.e176-e182

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Clinical cancer research, 2014-01, Vol.20 (2), p.490-498

2014

Link zum Volltext

Verfügbarkeit prüfen

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Blood, 2016-09, Vol.128 (12), p.1562-1566

2016

Link zum Volltext

Verfügbarkeit prüfen

Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report

Medicine (Baltimore), 2017-12, Vol.96 (51), p.e9452-e9452

2017

Link zum Volltext

Verfügbarkeit prüfen

Structures of Protection?: Rethinking Refugee Shelter

1st edition, 2020

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of day-1, day-3, and blastocyst cryopreserved embryo transfers

Fertility and sterility, 2010-03, Vol.93 (4), p.1353-1355

2010

Link zum Volltext

Verfügbarkeit prüfen

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Journal of hematology and oncology, 2014-03, Vol.7 (1), p.24-24, Article 24

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Journal of hematology and oncology, 2012-04, Vol.5 (1), p.18-18, Article 18

2012

Link zum Volltext

Verfügbarkeit prüfen

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

Leukemia & lymphoma, 2016-08, Vol.57 (8), p.1848-1855

2016

Link zum Volltext

Verfügbarkeit prüfen

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Leukemia, 2021-10, Vol.35 (10), p.2854-2861

2021

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.229-229

2021

Link zum Volltext

Verfügbarkeit prüfen

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen

Leukemia & lymphoma, 2020-12, Vol.61 (14), p.3484-3492

2020

Link zum Volltext

Verfügbarkeit prüfen

Designing a resilient network of marine protected areas for Kimbe Bay, Papua New Guinea

Oryx, 2009-10, Vol.43 (4), p.488-498

2009

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients

Pharmacotherapy, 2017-04, Vol.37 (4), p.420-428

2017

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Leukemia & lymphoma, 2014-10, Vol.55 (10), p.2328-2334

2014

Link zum Volltext

Verfügbarkeit prüfen

Bicycle tire inflator as carbon dioxide source for anesthesia apparatus checkout

Anesthesia and analgesia, 2010-03, Vol.110 (3), p.974-974

Smith, Scott E

2010

Link zum Volltext

Verfügbarkeit prüfen

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

Blood advances, 2024-06, Vol.8 (12), p.3189-3199

2024

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome

Cancer, 2012-04, Vol.118 (8), p.2138-2147

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 5.595

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.983)
Mit Volltextzugriff
(4.945)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.648)
Life Sciences & Biomedicine
(2.783)
Humans
(2.250)
Female
(1.241)
Male
(1.240)
Biological And Medical Sciences
(787)
Middle Aged
(711)
Adult
(709)
Physical Sciences
(653)
Medical Sciences
(610)
Animals
(590)
Aged
(513)
Risk Factors
(306)
Adolescent
(300)
Science & Technology - Other Topics
(289)
Child
(285)
Multidisciplinary Sciences
(272)
General & Internal Medicine
(247)
Social Sciences
(244)
Physics
(239)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern Era

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report

Structures of Protection?: Rethinking Refugee Shelter

Outcomes of day-1, day-3, and blastocyst cryopreserved embryo transfers

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen

Designing a resilient network of marine protected areas for Kimbe Bay, Papua New Guinea

Evaluation of Risk Factors for Clostridium difficile Infection in Hematopoietic Stem Cell Transplant Recipients

Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy

Bicycle tire inflator as carbon dioxide source for anesthesia apparatus checkout

Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate‐1 risk myelodysplastic syndrome

Suchergebnisse filtern